A PHARMA CONGRESS CONFERENCE A Hybrid Conference, Internet Event & Training Tool

Transcription

1 SECOND ANNUAL SUMMIT ON Disclosure,Transparency and Aggregate Spend for Drug, Device and A PHARMA CONGRESS CONFERENCE Biotech Companies March 3 5, 2010 Silver Grantor: Bronze Grantors: A Hybrid Conference, Internet Event & Training Tool See pg. 2 Renaissance Washington DC Hotel The Disclosure Summit is dedicated to the memory of Mike Bigelow, Former Assistant General Counsel at Eli Lilly ( ) Co chairs: Eve Costopoulos, Vice President, Corporate Compliance, Schering-Plough Jonathon Kellerman, Principal, Pharmaceutical and Life Sciences Advisory Services, PricewaterhouseCoopers LLP Daniel A. Kracov, Esq., Partner, Arnold & Porter Paul J. Silver, Managing Director, Huron Consulting Group, LLC Jack T. Tanselle, Director, Navigant Consulting Michael Varlotta, Senior Director, Department of Medical Education, Medical Affairs, Centocor Federal & State Policymakers: Christopher J. Armstrong, Esq., Investigative Counsel, Senate Committee on Finance Jack Mitchell, Chief of Oversight and Investigations, Senate Special Committee on Aging George Till, MD, State Legislator, Vermont Federal & State Prosecutors: Julie Brill, Esq., Senior Deputy Attorney General, North Carolina Department of Justice James G. Sheehan, Esq., New York State Medicaid Inspector General Gerald Sullivan, Esq., AUSA, US Attorney s Office, Eastern District of Pennsylvania Policy Experts: M. Chisolm, III, PhD, Vice Chair, Lerner Research Institute, Cleveland Clinic Allan Coukell, Director of Policy, Prescription Project Bernard Lo, MD, Professor of Medicine and Director, Program in Medical Ethics, University of California, San Francisco Frank W. LoGerfo, MD, William V. McDermott Distinguished Professor of Surgery, Harvard Medical School James Roosevelt, Jr., Esq., President and Chief Executive Officer, Tufts Health Plan Thomas P. Stossel, MD, Director, Translational Medicine Division, Senior Physician, Brigham & Women s Hospital Compliance Professionals and Inhouse Counsel: Diane Cruz-Burke, Esq., Assistant General Counsel, Eli Lilly Kevin T. Gordon, Associate Director, Application and Data Services, Cephalon Jacqueline K. Huber, Corporate Vice President and Chief Compliance Officer, Biomet Beth Margerison, Director, Regulatory Compliance, Ethics and Compliance, Novartis Pharmaceuticals Corporation Brian S. McGowan, PhD, CCMEP, Senior Director, Independent Medical Education, Pfizer Jeffrey S. Paden, Compliance Officer, GlaxoSmithKline Heather Reilly Powell, Esq., Director, Compliance Training and Reporting, Daiichi Sankyo Geralyn Ritter, Vice President, Global Public Policy and Corporate Responsibility, Merck Trudy J. Seeley, Esq., Compliance Manager, State Law Compliance, and US Corporate Compliance, sanofi-aventis Betsy Van Hecke, Vice President Ethics and Compliance, MedTronic Compliance Technology Experts: Michael Bell, Esq., President, R-Squared Mitch Chi, SVP Sales, Health Market Science John Cunningham, Sales Director, Cegedim Dendrite John Patrick Oroho, Esq., EVP, Porzio Pharmaceutical Services Advisors & Legal Counsel: John T. Bentivoglio, Esq., Partner, Skadden Arps LLP Daniel F. Donovan, III, Esq., Partner, King & Spalding Michael N. Druckman, Esq., Partner, Hogan & Hartson Kim Life, Esq., Principal, Life Compliance Solutions William A. Sarraille, Esq., Partner, Sidley Austin LLP

2 The Time is Now for New, Efficient and Cost-Effective Alternatives to Traditional Learning Approaches! MANY DIFFERENT FORCES the nation s economic crisis, costly and difficult air travel, the mandate for cost efficiency in healthcare, the proliferation of greater Internet bandwidth, the emergence of the popularity of online video via YouTube, and the explosion of online training in the health sector have come together to create both a dramatic need and an extraordinary opportunity for innovative approaches to sharing new ideas and best practices. This Summit offers not only traditional conference attendance, but also the opportunity to attend the event live and archived online. How can we be expected to reform the nation s health system if we cannot reform the way we do our own business? Content Options Traditional Conference Registration Register for Preconference Disclosure Boot Camp and/or Conference. Disclosure Training Program The Second Annual Summit on Disclosure, Transparency and Aggregate Spend for Drug, Device and Biotech Companies is offering a Disclosure Training Program in the form of an optional course within the conference for attendees wishing to take a deeper dive into the Summit s subject matter. The Program requirements are: Completion of preconference readings Completion of five online course modules on Disclosure prepared by Arnold & Porter and Huron Consulting Consideration of a series of preconference questions Attend Preconference Disclosure Summit Boot Camp either in person or online Attendance at Summit either in person or online Successful completion of a post-conference online examination Attendees who successfully complete all program requirements will receive a certificate of completion. This certificate is evidence that has successfully completed the Disclosure Training Program Offered at the Summit on Disclosure, Transparency and Aggregate Spend for Drug, Device & Biotech Companies March 4 5, 2010 in Disclosure Boot Camp Online Training Modules MODULE 1 Background on Disclosure MODULE 2 Understanding Current Disclosure Challenges MODULE 3 Preparing for Future Disclosure Challenges History of disclosure controversies Conflicts of interest Roles of physicians working with pharmaceutical and device companies The general drug/device compliance framework Corporate transparency initiatives Recent settlements/cias Physician disclosure obligations (e.g., academic institutions, NIH, etc.) PhRMA and AdvaMed codes Off-Label Monitoring Overview of Aggregate Spend challenges Review of state disclosure and licensure approaches, and related requirements Maine DC Minnesota California Other West Virginia Massachusetts Vermont Nevada Understanding reporting infrastructure and technology challenges Pending Federal Physician Payments Sunshine Act Breadth Definitions Requirements Processes Preemption MedPAC recommendations Clinical Trials (ClinicalTrials.gov) Understanding the disclosure environment Understanding current legal obligations Preparing for potential future challenges Participation Options Traditional Onsite Attendance Simply register, travel to the conference city and attend in person. PROS: subject matter immersion; professional networking opportunities; faculty interaction. Live and Archived Internet Attendance Watch the conference in live streaming video over the Internet and at your convenience at any time 24/7 for six months immediately following the event. The archived conference includes speaker videos and coordinated PowerPoint presentations. PROS: Live digital feed and 24/7 Internet access for next six months; accessible in office, at home or anywhere worldwide with Internet access; avoid travel expense and hassle; no time away from the office. Onsite At your office or home The Group Registration/ Online Training Alternative By arranging to license online group access to the Summit Disclosure Training Program, pharmaceutical, device and biotech companies subject to disclosure and aggregate spend requirements can implement company-wide online training programs. The company training coordinator can assign and track online participation. Successful completion of the training can be evidenced by passing the post-conference training examination. An Example of a Pharma Company Disclosure Training Program: MODULE 4 Assessing Internal Preparedness for Disclosure MODULE 5 Executing and Maintaining a Successful Disclosure Program Educating stakeholders Benchmarking Assessing existing systems, policies and procedures Addressing gaps Voluntary disclosures and corrections Assessing the public impact of future disclosures Development of compliant policies and procedures Training IT system challenges Addressing public reactions to disclosure Conducting internal reviews/audits Investigations Continuous improvement Preparing for disclosure compliance Successful execution and maintaining compliance 2

3 SECOND ANNUAL SUMMIT ON DISCLOSURE,TRANSPARENCY AND AGGREGATE SPEND FOR DRUG, DEVICE AND BIOTECH COMPANIES Sales and marketing disclosure initiatives are sweeping the pharmaceutical and medical device industries. New Jersey recently became the latest state to propose a broad set of disclosure requirements. Meanwhile, competing versions of the Physician Payments Sunshine Act have been included in the House and Senate healthcare reform bills moving through Congress. If the Sunshine Act is passed, drug and device companies will have a broad new federal requirement with which to comply. If it is not, the states are prepared to fill the void with a patchwork of inconsistent requirements, and the Sunshine Act will likely be moved forward as freestanding legislation next year. Meanwhile, the HHS Office of Inspector General has made disclosure requirements a standard feature of corporate integrity agreements (CIA). In addition, state Attorneys General are pushing the envelope with their own disclosure requirements included in state settlements. The influential Institute of Medicine (IOM) recently gave the issue further impetus when it recommended disclosure reforms and a growing list of academic medical centers have entered the act with their own independent requirements. The Second Annual Summit on Disclosure, Transparency and Aggregate Spend for Drug, Device, and Biotech Companies will examine these numerous mandates and how companies are responding. Expert panels will explore the latest state and federal initiatives and how regulators and enforcers view disclosure as a compliance tool. Case studies will examine how companies can effectively comply with overlapping requirements while adding value to the company's bottom line. The Summit brings together the key players shaping disclosure initiatives with the in-house and outside experts developing programs to comply in a cost-effective fashion. Preconference Disclosure Summit Boot Camp: Understanding the Forces Driving Disclosure: State Legislators, MedPAC, US Congress: The Sunshine Act, State Enforcers, OIG, Settlements and CIAs The Transparency and Disclosure Field Guide The Nuts and Bolts of an Aggregate Spend Program The Summit: How Disclosure and Transparency are Reshaping Pharmaceutical and Device Marketing and Compliance The Sunshine Act and Health Reform Pushing the Envelope: What s Next for the States? The Evolving Role of the OIG Federal and State Enforcement Initiatives How Transparency Will Impact Government Enforcement and Private Litigation Evolving ACCME Disclosure Requirements Emergence of Institutional Gift Bans and Disclosure Requirements IOM Recommendations Benchmarking: An Overview of Company Aggregate Spend Compliance Practices Today Early Lessons from Initial Voluntary Public Disclosures Capturing Correct Information and Ensuring Accuracy Agenda: Wednesday, March 3, 2010 Preconference: Disclosure Summit Boot Camp 1:30 pm Welcome and Preconference Overview Daniel A. Kracov, Esq., Partner, Arnold & Porter, (Co chair) Paul J. Silver, Managing Director, Huron Consulting Group, LLC, Atlanta, GA (Co chair) 1:45 pm Understanding the Forces Driving Disclosure: State Legislators, MedPAC, US Congress: Health Reform and the Sunshine Act, State Enforcers: Eli Lilly s Zyprexa Settlement, The HHS Office of Inspector General, and Cephalon and Other Recent CIAs Jeffrey L. Handwerker, Esq., Partner, Arnold & Porter, 2:30 pm The Transparency and Disclosure Field Guide: Navigating a Compliant Pathway Eric M. Baim, Esq., Associate, Hogan & Hartson, 3:15 pm Break 3 3:45 pm The Nuts and Bolts of an Aggregate Spend Program Marci Juneau, Manager, Life Sciences Advisory Services, Huron Consulting Group, Atlanta, GA Manny Tzavlakis, Director, Life Sciences Advisory Services, Huron Consulting Group, New York, NY 4:30 pm Faculty Questions & Answers 5:00 pm Preconference Adjournment Hotel Information A special, group rate of $ single/double per night (plus tax) has been arranged for Disclosure Summit attendees. Please make reservations by calling and ask for Disclosure Summit to receive the group rate. For information on how to book your hotel room online, please go to the travel tab at Reservations at the special group rate will be accepted until Thursday, February 11, After this date, reservations will be accepted on a space-available basis at the prevailing rate. Renaissance Washington DC Hotel 999 Ninth Street NW Reservations:

4 Thursday, March 4, 2010 DAY I: THE PERFECT STORM: DISCLOSURE GRIPS THE DRUG AND DEVICE INDUSTRIES 7:00 am Registration Commences PART I:THE MARKETPLACE, POLITICAL AND REGULATORY CONTEXT 8:00 am Welcome and Overview Eve Costopoulos, Vice President, Global Compliance, Schering-Plough Corporation, Kenilworth, NJ (Co chair) Jonathon Kellerman, Principal, Pharmaceutical and Life Sciences Advisory Services, PricewaterhouseCoopers LLP, Florham Park, NJ (Co chair) 8:15 am How Disclosure and Transparency are Reshaping Pharmaceutical and Device Marketing and Compliance Eve Costopoulos, Vice President, Global Compliance, Schering-Plough Corporation, Kenilworth, NJ William A. Sarraille, Esq., Partner, Sidley Austin, 9:00 am The Sunshine Act and Health Reform Christopher J. Armstrong, Esq., Investigative Counsel, Committee on Finance, US Senate, Staff, Senator Charles E. Grassley (R-IA), Ranking Member, Jack Mitchell, Chief of Oversight and Investigations, Special Committee on Aging, US Senate, Staff, Senator Herb Kohl (D/WI) Daniel F. Donovan, III, Esq., Partner, Government Advocacy and Public Policy Practice Group, King & Spalding, Former Senior Investigative Counsel to Senator Charles E. Grassley (R-IA), Committee on Finance, US Senate, (Moderator) 9:45 am What s Next for the States: Pushing the Envelope on Disclosure and Gift Bans Julie Brill, Esq., Senior Deputy Attorney General, Chief, Consumer Protection Division, North Carolina Department of Justice, Raleigh, NC Allan Coukell, Director of Policy, Prescription Project, Winner, 2007 Edward R. Murrow Award, Boston, MA Melissa J. Lopes, Esq. (Invited), Deputy General Counsel, Massachusetts Department of Public Health, Boston, MA George Till, MD, State Legislator, Vermont, Jericho, VT Jack T. Tanselle, Director, Navigant Consulting, Inc., Chicago, IL (Moderator) 11:00 am The Evolving Role of the OIG Mary E. Riordan, Esq. (Invited), Senior Counsel, Office of Counsel to the Inspector General, Office of Inspector General, US Department of Health and Human Services, 11:45 am Networking Luncheon and Table Topics 1:00 pm Federal and State Enforcement Initiatives Federal Enforcement Initiatives and Non-Disclosure Risks: Certifications, Research, and Online Advertising Gerald Sullivan, Esq., Assistant United States Attorney, US Attorney s Office, Eastern District of Pennsylvania, Philadelphia, PA How Disclosure Will Reshape State Enforcement Initiatives James G. Sheehan, Esq., New York State Medicaid, Inspector General, Former Associate United States Attorney, US Attorney s Office, Eastern District of Pennsylvania, Albany, NY Faculty Questions & Answers Daniel A. Kracov, Esq., Partner, Arnold & Porter, (Moderator) 2:00 pm How Transparency Will Impact Government Enforcement and Private Litigation John T. Bentivoglio, Esq., Partner, Skadden Arps LLP, Former Special Counsel for Healthcare Fraud and Chief Privacy Officer, US Department of Justice, 2:30 pm Evolving ACCME Disclosure Requirements Brian S. McGowan, PhD, CCMEP, Senior Director, Independent Medical Education, Pfizer, Former Executive Director, The FCG Institute for Continuing Education, Former Senior Manager, Medical Education at Cephalon, Inc., Collegeville, PA Thomas Sullivan, President and Founder, Rockpointe Corporation, Columbia, MD 3:15 pm Break 3:45 pm The Emergence of Institutional Gift Bans and Disclosure Requirements Guy M. Chisolm, III, PhD, Vice Chair, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 4:15 pm IOM Recommendations Regarding New Voluntary and Regulatory Measures to Strengthen Protections Against Financial Conflicts of Interest in Medicine without Hindering Patient Care or the Advancement of Medical Knowledge Bernard Lo, MD, Professor of Medicine and Director, Program in Medical Ethics, Department of Medicine, University of California, San Francisco, Chair, Committee on Conflict of Interest in Medical Research, Education, and Practice, Institute of Medicine, San Francisco, CA 10:30 am Break 4

5 PART II: HOW TO ESTABLISH EFFECTIVE DISCLOSURE PROTOCOLS AND AGGREGATE SPEND PROGRAMS 4:45 pm Benchmarking: An Overview of Company Aggregate Spend Compliance Practices Today and How to Take Your Program to the Next Level Paul J. Silver, Managing Director, Practice Leader, Life Sciences Advisory Services, Huron Consulting Group, Atlanta, GA 5:15 pm Early Lessons from Initial Voluntary Public Disclosures Diane Cruz-Burke, Esq., Assistant General Counsel, Eli Lilly and Company, Indianapolis, IN Jeffrey S. Paden, Compliance Officer, GlaxoSmithKline North America, Durhan, NC Geralyn Ritter, Vice President, Global Public Policy and Corporate Responsibility, Merck & Co., Inc., Former Senior Vice President, International Affairs, PhRMA, Whitehouse Station, NJ Betsy Van Hecke, Vice President Ethics and Compliance, MedTronic Spinal and Biologics, Minneapolis, MN Paul J. Silver, Managing Director, Practice Leader, Life Sciences Advisory Services, Huron Consulting Group, Atlanta, GA (Moderator) 6:00 pm Capturing Correct Information and Ensuring Accuracy Beth Margerison, Director, Regulatory Compliance, Ethics and Compliance, Novartis Pharmaceuticals Corporation, East Hanover, NJ Jon Wilkenfeld, President, Potomac River Partners, Vienna, VA 6:30 pm Adjournment and Networking Reception Friday, March 5, 2010 DAY II: HOW TO ESTABLISH EFFECTIVE DISCLOSURE PROTOCOLS AND AGGREGATE SPEND PROGRAMS (Continued) 8:00 am Welcome and Introduction to Day Two Jack T. Tanselle, Director, Navigant Consulting, Inc., Chicago, IL (Co chair) Michael Varlotta, Senior Director, Department of Medical Education, Medical Affairs, Centocor, a wholly owned subsidiary of Johnson & Johnson, Horsham, PA (Co chair) 8:15 am Auditing and Monitoring Your Aggregate Spend Program Sarah K. Giesting, Esq., Associate, Epstein Becker & Green, New York, NY Heather Reilly Powell, Esq., Director, Compliance Training and Reporting, Daiichi Sankyo, Inc., Former Associate Director, Global Compliance, Cephalon, Inc., Parsippany, NJ 8:45 am Aggregate Spend Return on Investment (ROI): Making a Business Case of your Aggregate Spend Program Rore Middleton (Invited), Corporate Compliance Consultant, Purdue Pharma, Stamford, CT 9:15 am Applying Business Process Management Strategies to Improve Aggregate Spend Reporting Jennifer Colapietro, Director, PricewaterhouseCoopers Pharmaceutical and Life Sciences Advisory Services, Florham Park, NJ 9:45 am How to Successfully Manage Information Technology for Aggregate Spend Kevin Gordon, Associate Director, Application and Data Services, Cephalon, Frazer, PA 10:30 am Break Remembering Mike Bigelow MIKE BIGELOW, ESQ., Assistant General Counsel at Eli Lilly, passed away in April of this year of complications from pancreatic cancer. He was 41 years old. In March 2009 Mike traveled to Washington, DC to deliver a presentation at the First Summit on Disclosure, Transparency and Aggregate Spend for Drug, Device and Biotech Companies. Mike was a leader on pharmaceutical compliance and a very decent man who faced his gravest challenge with an uncommon degree of dignity. MEMORIAL CONTRIBUTIONS: Mike requested that memorial contributions be made to his children s college education account. Please make any memorial checks payable to: CollegeChoice Advisor 529 Plan. They can be sent to: Sanderling Trace, Fishers, IN :00 am Aggregate Spend Technology Solutions Roundtable Michael Bell, Esq., President, R-Squared, Princeton, NJ Mitch Chi, Senior Vice President, Sales, Health Market Science, King of Prussia, PA John Cunningham, Sales Director, Cegedim Dendrite, Richmond, VA John Patrick Oroho, Esq., Executive Vice President, Porzio Pharmaceutical Services, Principal, Porzio, Bromberg & Newman PC, Morristown, NJ David Wysocky, Director, PricewaterhouseCoopers Pharmaceutical and Life Sciences Advisory Services, Boston, MA Kim Life, Esq., Principal, Life Compliance Solutions, Former Associate Director, Business Conduct, Gilead Sciences, San Francisco, CA (Moderator) 12:30 pm Networking Luncheon 5

6 1:15 pm How to Implement an Effective Aggregate Spend Sales Force Training Program Ed Schreiber, Esq. (Invited), Assistant General Counsel, CR Bard, Murray Hill, NJ 1:45 pm How to Manage New Clinical Trial Disclosure Requirements Michael N. Druckman, Esq., Partner, Hogan & Hartson, Trudy J. Seeley, Esq., Compliance Manager, State Law Compliance and US Corporate Compliance, sanofi-aventis, Bridgewater, NJ 2:15 pm The Physician-Industry Relationship: Flaws and Solutions James Roosevelt, Jr., Esq., President and Chief Executive Officer, Tufts Health Plan, Past President, American Health Lawyers Association, Former Associate Commissioner for Retirement Policy, US Social Security Administration, Boston, MA Thomas P. Stossel, MD, Director, Translational Medicine Division, Senior Physician, Hematology Division, American Cancer Society Professor of Medicine, Brigham & Women s Hospital, Harvard Medical School, Boston, MA Frank W. LoGerfo, MD, William V. McDermott Distinguished Professor of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (Moderator) 3:00 pm Industry Disclosure Best Practice Roundtable Jacqueline K. Huber, Corporate Vice President and Chief Compliance Officer, Biomet, Inc.. Warsaw, IN Heather Reilly Powell, Esq., Director, Compliance Training and Reporting, Daiichi Sankyo, Inc., Former Associate Director, Global Compliance, Cephalon, Inc., Parsippany, NJ Ed Schreiber, Esq. (Invited), Assistant General Counsel, CR Bard, Murray Hill, NJ Trudy J. Seeley, Esq., Compliance Manager, State Law Compliance and US Corporate Compliance, sanofi-aventis, Bridgewater, NJ Michael Varlotta, Senior Director, Department of Medical Education, Medical Affairs, Centocor, a wholly owned subsidiary of Johnson & Johnson, Horsham, PA Jonathon Kellerman, Principal, Pharmaceutical and Life Sciences Advisory Services, PricewaterhouseCoopers LLP, Florham Park, NJ (Moderator) 4:00 pm Summit Adjournment istock Photo 2007 Asier Villafranca Velasco Save the Date! THE FOURTH INTERNATIONAL Pharmaceutical Regulatory and Compliance Congress May 17-18, 2010 Berlin, Germany Sponsored by THE FOLLOWING REGISTRATION TERMS AND CONDITIONS APPLY FOR THE DISCLOSURE SUMMIT: REGARDING INTERNET REGISTRATIONS 1. Individuals or groups may register for Internet access. Organizations may register for group access without presenting specific registrant names. In such instances the registering organization will be presented a series of user names and passwords to distribute to participants. 2. Each registrant will receive a user name and password for access. Registrants will be able to change their user names and passwords and manage their accounts. 3. Internet registrants will enjoy six (6) months access from date of issuance of user name and password. 4. Only one user (per user name and password) may view or access archived conference. It is not permissible to share user name and password with third parties. Should Internet registrants choose to access post conference content via alternative media (ipod Touch, DVD-ROM and Flash Drive), this individual use limitation applies. It is not permissible to share alternative media with third parties. 5. User name and password use will be monitored to assure compliance. 6. Each Internet registration is subject to a bandwidth or capacity use cap of 5 gb per user per month. When this capacity use cap is hit, the registration lapses. Said registration will be again made available at start of next month so long as registration period has not lapsed and subject to same capacity cap. 6 REGARDING ONSITE REGISTRATION, CANCELLATIONS AND SUBSTITUTIONS 1. For onsite group registrations, full registration and credit card information required for each registrant. List all members of groups registering concurrently on fax or scanned cover sheet. 2. For onsite registrants there will be no refunds for no-shows or for cancellations. You may send a substitute; please call the Conference Office at (800) or (206) for further information. METHOD OF PAYMENT FOR TUITION Make payment to Health Care Conference Administrators LLC by check, MasterCard, Visa or American Express. Credit card charges will be listed on your statement as payment to Health Care Conference Administrators LLC. Checks or money orders should be made payable to Health Care Conference Administrators LLC. A $20 fee will be charged on any returned checks. PAYMENT OPTIONS Registration may be made online or via mail, fax or scan. You may register online at Alternatively, you may use our printed registration form, enclose payment and return it to the Summit registrar at 3291 West Wilson Road, Pahrump, NV 89048, or fax the completed form to continued next page

7 SECOND ANNUAL SUMMIT ON DISCLOSURE, TRANSPARENCY AND AGGREGATE SPEND FOR DRUG, DEVICE AND BIOTECH COMPANIES REGISTRATION FORM HOW TO REGISTER: Fully complete the following (one form per registrant, photocopies acceptable). Payment must accompany each registration (U.S. funds, payable to Health Care Conference Administrators, LLC). ONLINE: Secure online registration at FAX: (include credit card information with registration) MAIL: Conference Office, 3291 West Wilson Road, Pahrump, NV FOR REGISTRATION QUESTIONS: PHONE: (800) (Continental US, Alaska and Hawaii only) or (206) , Monday-Friday, 9 AM - 5 PM PST registration@hcconferences.com (Registration is not available by phone or .) ONSITE CONFERENCE ATTENDANCE Onsite conference registration includes onsite attendance, professional networking, and live interaction with the faculty, plus a conference materials DVD. INDIVIDUAL REGISTRATION: PRECONFERENCE REGISTRATION: Preconference: Disclosure Summit Bootcamp (March 3, 2010) $ 495 CONFERENCE REGISTRATION: (March 4-5, 2010; does not include Preconference): Through Friday, January 1, 2010 $1,395 Through Friday, January 29, 2010 $1,595 After Friday, January 29, 2010 $1,795 DISCLOSURE TRAINING PROGRAM: (Includes preconference readings and questions, online courses and post-conference online examination. Requires preconference and conference registration.) $ 395 GROUP REGISTRATION DISCOUNT: Three or more registrations submitted at the same time receive the following discounted rates for conference registration only: Conference: Through Friday, January 1, 2010 $1,095 Through Friday, January 29, 2010 $1,295 After Friday, January 29, 2010 $1,495 COMPLETE THE FOLLOWING. PLEASE PRINT: NAME SIGNATURE OF REGISTRANT - REQUIRED JOB TITLE ORGANIZATION DEPARTMENT ADDRESS CITY/STATE/ZIP TELEPHONE FAX - Please include fax number if you wish to receive a confirmation letter. Special Needs (Dietary or Physical) ONLINE CONFERENCE ATTENDANCE All online registrants are automatically registered for ALL Summit events the preconference boot camp, the conference, and the Disclosure Training Program. Online conference registration includes the live Internet feed from the Summit, plus six months of continued archived Internet access, available 24/7. INDIVIDUAL REGISTRATION: Includes preconference boot camp, conference and Disclosure Training Program exam: Through Friday, January 1, 2010 $ 995 Through Friday, January 29, 2010 $1,195 After Friday, January 29, 2010 $1,395 GROUP REGISTRATION DISCOUNT: GROUP REGISTRATION offers the substantial volume discounts set forth below. All group registrants are enrolled in the preconference, conference and Disclosure Training Program examination. Group registration offers the possibility of implementing a disclosure online training program. Group registration permits the organizational knowledge coordinator either to share conference access with colleagues or to assign and track conference participation to employees. Certificate of successful completion of online postconference examination evidence mastery of conference body of knowledge. Conference Access: 5 or more $595 each 20 or more $395 each 10 or more $495 each 40 or more $295 each See INTELLECTUAL PROPERTY POLICY policy below. Terms and Conditions, continued or scan the completed form to registration@hcconferences.com. Checks or money orders should be made payable to Health Care Conference Administrators LLC. The following credit cards are accepted: American Express, Visa or MasterCard. Credit card charges will be listed on your statement as payment to Health Care Conference Administrators LLC. For registrants awaiting company check or money order, a credit card number must be given to hold registration. If payment is not received by seven days prior to the Summit, credit card payment will be processed. TAX DEDUCTIBILITY Expenses of training including tuition, travel, lodging and meals, incurred to maintain or improve skills in your profession may be tax deductible. Consult your tax advisor. Federal Tax ID: INTELLECTUAL PROPERTY POLICY Unauthorized sharing of Summit content via Internet access through the sharing of user names and passwords or via alternative media (ipod Touch, DVD-ROM and Flash Drive) through the sharing of said media is restricted by law and may subject the copyright infringer to substantial civil damages. The Summit aggressively pursues copyright infringers. If a registrant needs the ability to share Summit content within his or her organization, multiple Summit registrations are available at discounted rates. The Summit will pay a reward for information regarding unauthorized sharing of Summit content. The reward will be one half of any recovery resulting from a copyright infringement (less legal fees and other expenses related to the recovery) up to a maximum reward payment of $25,000. The payment will be made to the individual or individuals who in the opinion of our legal counsel first provided the factual information, which was necessary for the recovery. If you have knowledge regarding the unauthorized Summit content sharing, contact the Summit registration office. GENERAL TERMS AND CONDITIONS The Summit program is subject to change. An executed registration form constitutes binding agreement between the parties. FOR FURTHER INFORMATION Call (800) or (206) , send to registration@hcconferences.com, or visit our website at 7 PAYMENT DISCOUNT CODE TOTAL FOR ALL OPTIONS, ONSITE OR ONLINE: Please enclose payment with your registration and return it to the Registrar at The Disclosure Summit, 3291 West Wilson Road, Pahrump, NV 89048, or fax your credit card payment to You may also register online at Check/money order enclosed (payable to Health Care Conference Administrators LLC) Payment by credit card: American Express Visa Mastercard If a credit card number is being given to hold registration only until such time as a check is received it must be so noted. If payment is not received by seven days prior to the Summit, the credit card payment will be processed. Credit card charges will be listed on your statement as payment to Health Care Conference Administrators LLC. TOTAL $ ACCOUNT # EXPIRATION DATE NAME OF CARDHOLDER SIGNATURE OF CARDHOLDER

8 Second Annual Summit ondisclosure, Transparency and Aggregate Spend for Drug, Device and Biotech Companies Publications Printing Dept Corporate Way Palm Desert, CA USA (Address for Return Mail Only) PRESORTED FIRST CLASS U.S. POSTAGE PAID PERMIT # 1 PALM DESERT, CA Forwarding Service Requested SECOND ANNUAL Disclosure,Transparency and SUMMIT ON Aggregate Spend for Drug, Device and Biotech Companies A PHARMA CONGRESS CONFERENCE March 3 5, 2010 Renaissance Washington DC Hotel A Hybrid Conference, Internet Event & Training Tool See pg. 2